INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Public company

MISTMilestone Pharmaceuticals Inc.

CIK 0001408443

EDGAR filingsOpen in network
Disclosed transactions30
Buys / sells0 / 8
Max Insider Score66
Connections6with evidence

MIST · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
DS
Duty StuartDirector
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
77.0K sh
Jun 10, 2026Jun 12, 2026
traded Jun 10, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Duty StuartDirector · Jun 12, 2026
  • ← Insider ofevidence
    Nelson Jeffrey EdwardChief Operating Officer · Jan 28, 2026
  • ← Insider ofevidence
    Bharucha DavidChief Medical Officer · Jan 28, 2026
5
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A
—
136.0K sh
Feb 2, 2026
Feb 4, 2026
traded Feb 2, 2026
+2d
SEC FORM 4

Evidence

5
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
204.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

5
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
136.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

5
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
204.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

24
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
100.0K sh
Dec 12, 2025Jan 28, 2026
traded Dec 12, 2025
+47dSEC FORM 4

Evidence

66
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Open-market sale
SELL$135K
58.0K sh
Dec 15, 2025Jan 28, 2026
traded Dec 15, 2025
+44dSEC FORM 4

Evidence

13
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Option exercise
M—
20.1K sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

36
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Open-market sale
SELL$24K
12.2K sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

24
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
100.0K sh
Dec 12, 2025Jan 28, 2026
traded Dec 12, 2025
+47dSEC FORM 4

Evidence

17
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Option exercise
M—
20.1K sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

36
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
100.0K sh
Dec 12, 2025Jan 28, 2026
traded Dec 12, 2025
+47dSEC FORM 4

Evidence

24
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
100.0K sh
Dec 12, 2025Jan 28, 2026
traded Dec 12, 2025
+47dSEC FORM 4

Evidence

17
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Option exercise
M—
20.1K sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

36
HA
Hasija AmitCFO & EVP of Corp. Development
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
100.0K sh
Dec 12, 2025Jan 28, 2026
traded Dec 12, 2025
+47dSEC FORM 4

Evidence

62
HA
Hasija AmitCFO & EVP of Corp. Development
MISTMilestone Pharmaceuticals Inc.
Open-market sale
SELL$135K
58.0K sh
Dec 15, 2025Jan 28, 2026
traded Dec 15, 2025
+44dSEC FORM 4

Evidence

13
HA
Hasija AmitCFO & EVP of Corp. Development
MISTMilestone Pharmaceuticals Inc.
Option exercise
M—
20.1K sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

36
HA
Hasija AmitCFO & EVP of Corp. Development
MISTMilestone Pharmaceuticals Inc.
Open-market sale
SELL$24K
12.2K sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

24
HA
Hasija AmitCFO & EVP of Corp. Development
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
100.0K sh
Dec 12, 2025Jan 28, 2026
traded Dec 12, 2025
+47dSEC FORM 4

Evidence

36
ML
Muller LorenzChief Commercial Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
100.0K sh
Dec 12, 2025Jan 28, 2026
traded Dec 12, 2025
+47dSEC FORM 4

Evidence

62
ML
Muller LorenzChief Commercial Officer
MISTMilestone Pharmaceuticals Inc.
Open-market sale
SELL$124K
53.6K sh
Dec 15, 2025Jan 28, 2026
traded Dec 15, 2025
+44dSEC FORM 4

Evidence

9
ML
Muller LorenzChief Commercial Officer
MISTMilestone Pharmaceuticals Inc.
Option exercise
M—
20.1K sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

36
ML
Muller LorenzChief Commercial Officer
MISTMilestone Pharmaceuticals Inc.
Open-market sale
SELL$22K
11.2K sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

24
ML
Muller LorenzChief Commercial Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
100.0K sh
Dec 12, 2025Jan 28, 2026
traded Dec 12, 2025
+47dSEC FORM 4

Evidence

17
ML
Muller LorenzChief Commercial Officer
MISTMilestone Pharmaceuticals Inc.
Option exercise
M—
20.1K sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

17
HA
Hasija AmitCFO & EVP of Corp. Development
MISTMilestone Pharmaceuticals Inc.
Option exercise
M—
20.1K sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

62
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Open-market sale
SELL$135K
58.0K sh
Dec 15, 2025Jan 28, 2026
traded Dec 15, 2025
+44dSEC FORM 4

Evidence

9
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Option exercise
M—
20.1K sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

36
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Open-market sale
SELL$24K
12.2K sh
Jan 26, 2026Jan 28, 2026
traded Jan 26, 2026
+2dSEC FORM 4

Evidence

16
ML
Muller LorenzChief Commercial Officer
MISTMilestone Pharmaceuticals Inc.
Gift
G—
25.0K sh
Dec 9, 2025Dec 11, 2025
traded Dec 9, 2025
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Hasija AmitCFO & EVP of Corp. Development · Jan 28, 2026
  • ← Insider ofevidence
    Muller LorenzChief Commercial Officer · Dec 11, 2025